Evercore ISI Reaffirms Their Hold Rating on Factset Research (FDS)
In a report released yesterday, David Motemaden from Evercore ISI maintained a Hold rating on Factset Research (FDS – Research Report), with a ...
Evercore ISI Sticks to Its Buy Rating for Vertiv Holdings (VRT)
Evercore ISI analyst Amit Daryanani maintained a Buy rating on Vertiv Holdings (VRT – Research Report) yesterday and set a price target of ...
ETF Daily News15d
Evercore ISI Reaffirms “In-Line” Rating for Veris Residential (NYSE:VRE)
NYSE:VRE opened at $16.89 on Wednesday. The stock’s 50 day moving average price is $16.06 and its 200 day moving average price is $16.97. Veris Residential has a 52 week low of $13.84 and a 52 ...
Investing23d
Evercore ISI sets Talen Energy stock Outperform with $287 target
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
Investing25d
Evercore ISI holds Booking Holdings stock Outperform rating
On Wednesday, Evercore ISI analysts maintained their Outperform rating on Booking Holdings (NASDAQ:BKNG) with a steady price target of $5,300.00. The analysts cited a potential modest beat and bracket ...
Yahoo Finance26d
Evercore adds Wendy’s to outperform list ahead of investor day
Investing.com -- Evercore ISI added Wendy’s Co to its Tactical Outperform list ahead of the company’s investor day on March 6, citing discounted valuation, a potential industry turnaround ...
ETF Daily News28d
Evercore ISI Upgrades CRISPR Therapeutics (NASDAQ:CRSP) to Outperform
CRSP stock opened at $49.72 on Friday. The business’s 50-day moving average price is $41.89 and its 200-day moving average price is $46.10. The stock has a market cap of $4.24 billion, a P/E ...
Nasdaq29d
Evercore ISI Group Upgrades CRISPR Therapeutics (BRSE:1CG)
Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (BRSE:1CG) from In-Line to Outperform. There are 577 funds or institutions reporting ...
Yahoo Finance1mon
CRISPR Therapeutics upgraded to Outperform by Evercore ISI
CRISPR Therapeutics (CRSP) shares jump after Evercore ISI upgraded the stock to Outperform from In Line. Julie Hyman and Josh Schafer examine what the analysts say about the biotech company on ...
Seeking Alpha1mon
CRISPR upped to outperform by Evercore on upcoming data
Evercore ISI has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to outperform from in line, citing upcoming catalysts. The investment firm said it was now including the CTX320 and CTX310 in vivo ...
Hosted on MSN1mon
Evercore ISI's Mark Mahaney likes Meta, but says other names will give more upside
Mark Mahaney, Evercore ISI head of internet research, joins 'Closing Bell' to discuss the markets, Meta's historic winning run and other plays he's watching in the market. Chiefs give Travis Kelce ...